Immune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker‐Guided Therapeutic Matching
Journal of Cellular Physiology · 2026-06 · 241 (6)
DOI: 10.1002/jcp.70197 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular Physiology, online erschienen am 07.06.2026. Verfasst von Xiaodong Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Peritoneal Neoplasms, Biomarkers, Tumor, Tumor Escape. Die Arbeit nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Huakang Public Welfare Foundation, Beijing Kechuang Medical Development Foundation, Beijing Life Oasis Public Welfare Service Center.
Abstract (Originalsprache)
Ovarian cancer peritoneal metastasis remains a major cause of recurrence and death despite advances in cytoreductive surgery, platinum‐based chemotherapy, PARP inhibition, and immune checkpoint blockade. The limited activity of immunotherapy in this setting reflects layered immune resistance shaped by impaired antigen visibility, redundant inhibitory receptor networks, suppressive myeloid and regulatory circuits, and metabolic‐epigenetic constraints within ascites and multicellular spheroids. These compartment‐specific features distinguish peritoneal disease from anatomically confined tumors and help explain why systemic immune reinvigoration alone rarely produces durable benefit. Here, we synthesize current evidence on the mechanisms that govern immune escape in ovarian cancer peritoneal dissemination, with emphasis on antigen presentation defects, checkpoint‐driven T‐cell exhaustion, anti‐phagocytic signaling, soluble suppressive mediators, and metabolic remodeling of the ascites microenvironment. We further examine how DNA damage response states intersect with innate immune sensing and discuss the translational implications of homologous recombination deficiency for combination treatment design. Finally, we propose a biomarker‐guided framework that links antigen‐presentation competence, immune engagement, dominant suppressive axes, and ascites‐specific biology to rational therapeutic matching. This mechanism‐centered view supports more precise trial design and provides a roadmap for combination immunotherapy in advanced ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of General Medicine, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China.
- Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China.
ORCID-Profile: Xiaodong Wang
Förderung
- Beijing Huakang Public Welfare Foundation
- Beijing Kechuang Medical Development Foundation
- Beijing Life Oasis Public Welfare Service Center
Zitieren
APA
Wang, X., Wang, J., Xiong, D., Cui, S., Wang, Q., Huang, Y., Ding, G., Tang, Y., & Feng, Y. (2026). Immune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker‐Guided Therapeutic Matching. Journal of Cellular Physiology, 241(6). https://doi.org/10.1002/jcp.70197
Vancouver
Wang X, Wang J, Xiong D, Cui S, Wang Q, Huang Y, et al. Immune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker‐Guided Therapeutic Matching. Journal of Cellular Physiology. 2026;241(6). doi:10.1002/jcp.70197
BibTeX
@article{Wang2026,
author = {Wang, Xiaodong and Wang, Junjie and Xiong, Di and Cui, Songli and Wang, Qianqian and Huang, Yiping and Ding, Gouping and Tang, Yixuan and Feng, Yeqian},
title = {Immune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker‐Guided Therapeutic Matching},
journal = {Journal of Cellular Physiology},
year = {2026},
volume = {241},
number = {6},
doi = {10.1002/jcp.70197}
}
EUVIMED